logo
NasdaqGM:PRCT logo

PROCEPT BioRobotics Community

NasdaqGM:PRCT Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 13 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

PRCT logo
PROCEPT BioRobotics
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts

US Medicare Coverage And Aquablation Trials Will Expand Patient Access

Key Takeaways Strong revenue growth driven by U.S. system demand and international sales, signaling potential for continued expansion. Favorable clinical trial results and upcoming Medicare coverage are set to boost system adoption and expand the patient market.
View narrative
US$76.88
FV
27.6% undervalued intrinsic discount
30.59%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
3 days ago author updated this narrative